Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02035072
Other study ID # IRST157.01
Secondary ID 2010-020379-22
Status Completed
Phase Phase 2
First received January 10, 2014
Last updated July 19, 2017
Start date November 2010
Est. completion date December 2016

Study information

Verified date July 2017
Source Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Title: Phase II study of hypofractionated radio-chemotherapy with gemcitabine plus oxaliplatin for unresectable nonmetastatic locally advanced pancreatic cancer.

Protocol code: IRST157.01

Phase: II

Study Design: monocentric, prospective, open-label not randomized trial.

Description of Study Treatment: radio-chemotherapy schedule

- GEMOX: Gemcitabine (GEM) 1000 mg/m2, day 1, and Oxaliplatin (OX) 100 mg/m2, day 2, every 2 weeks for 4 cycles.

- Hypofractionated radiotherapy (35 Gy in 7 fractions in 9 consecutive days, one session per day excluding Saturday and Sunday) administered 15 days after the 4th chemotherapy cycle.

- Further 4 cycles of GEMOX, starting 7-15 days after the end of the radiotherapy.

Objectives:

Step A: primary objective = to evaluate the safety of radiotherapy treatment. Secondary objective = the control of IM (internal margin) intra-fraction.

Step B: primary objective = to evaluate the proportion of the resectable patients after radio-chemotherapy. Secondary objectives = overall Response Rate (ORR); safety profile of combinated treatment;overall survival (OS); local progression free survival (LPFS) and progression free survival (PFS).

Statistical Considerations:

Step A:

Assuming that the probability to observe a toxicity involving the radiotherapy treatment discontinuation with the new treatment is less than 20%, 11 patients are to be evaluated for toxicity. If no toxicity involving the radiotherapy treatment discontinuation will be observed in 11 patients, the treatment can be considered safe with a probability > 90%. If 1 toxicity involving the radiotherapy treatment discontinuation will be observed, 7 more patients needs to be recruited. If no further toxicity involving the radiotherapy treatment discontinuation occurs, the treatment could be considered safe with a probability ≥ 90%.

If 2 or more toxicity involving the radiotherapy treatment discontinuation on 11 patients or 2 or more toxicity involving the radiotherapy treatment discontinuation on 18 patients will be observed, the study will be stopped because not safe and another kind of radiotherapy schedule must be designed.

Step B:

If the radiotherapy treatment will be considered no toxic, the study will continue in Step B : the goal of this phase II study is to increase the proportion of resectable patients of at least 15% with the new radio-chemotherapeutic treatment. By using the single-stage design (Gehan EA, J Chron Dis 1961) a total of 40 patients is required to be recruited in 2 years, and a further one-year period of follow-up is requested. If at least 7 patients out of 40 enrolled will be resectable, the hypothesis that the proportion of resectable patients will be less or equal to P1 (P1=the proportion of resectable patients with the new radio-chemotherapeutic treatment) will be refused and the treatment could be considered active.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date December 2016
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Patients with histologically or cytologically confirmed diagnosis of pancreatic cancer are candidates for the trial.

2. Stage III disease (AJCC TNM 6th edition, 2002). Inoperable disease, by radiological and surgical evaluation;

3. Age >18 years and =75 years.

4. Life expectancy of greater than 12 weeks.

5. ECOG performance status 0-2 (see Appendix A).

6. Presence of at least of one measurable lesion in agreement to RECIST criteria

7. Patients must have normal organ and marrow function as defined below:

- Leukocytes >3,000/uL

- Absolute neutrophil count >1,500/uL

- Platelets >100,000/uL

- Total bilirubin < 1.5 X ULN

- AST (SGOT)/ALT (SGPT) <2.5 X ULN

- Creatinine < 1.5 X ULN

8. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

9. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

1. Patients who have had any chemotherapy or radiotherapy prior to entering the study;

2. Stage IV disease;

3. Participation in another clinical trial with any investigational agents within 30 days prior to study screening.

4. Previous malignancy except cervical carcinoma in situ, adequately treated basal cell carcinoma, superficial bladder tumors, or other malignancies curatively treated >5 years before study entry.

5. History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine and oxaliplatin or other agents used in the study.

6. Active brain or leptomeningeal disease

7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Gemcitabine
Gemcitabine 1000 mg/m2
Oxaliplatin
Oxaliplatin 100 mg/m2
Radiation:
Hypofractionated RT
Hypofractionated radiotherapy (35 Gy in 7 fractions)

Locations

Country Name City State
Italy Radiotherapy Unit, IRCCS IRST Meldola FC

Sponsors (1)

Lead Sponsor Collaborator
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Toxicity If no toxicity in 11 patients, the treatment can be considered safe with a probability > 90%.
If 1 toxicity will be observed, 7 more patients needs to be recruited. If no further toxicity occurs, the treatment could be considered safe with a probability = 90%.
If 2 or more toxicity in 11 patients or 2 or more in18 patients will be observed, the study will be stopped because not safe.
15 months after the start of recruitment
Primary Proportion of resectable patients If at least 7 patients out of 40 enrolled will be resectable, the hypothesis that the proportion of resectable patients will be less or equal to P1 (P1=the proportion of resectable patients with the new radio-chemotherapeutic treatment) will be refused and the treatment could be considered active. 3 years after the start of recruitment
Secondary Objective tumor response It is assessed using RECIST (Response Evaluation Criteria in Solid Tumors) criteria. 3 years after the start of recruitment.
Secondary Objective tumor response rate (ORR) It is defined as the proportion of the intention-to-treat (ITT) population showing a complete or partial response, if confirmed = 4 weeks later. 3 years after the start of recruitment.
Secondary Overall survival (OS) It is counted from the date of registration to the date of death due to any cause or last date the patient was known to be alive (censored observation). 3 years after the start of recruitment
Secondary Progression free survival (PFS/local PFS) It is counted from the date of registration to the date of the first observation of documentation of objective disease progression/local disease progression or death due to any cause, whichever occurs first. 3 years after the start of recruitment
See also
  Status Clinical Trial Phase
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Completed NCT01628458 - Safety Study of Radiofrequency Ablation of Locally Advanced Pancreatic Cancer Phase 2
Not yet recruiting NCT04276857 - Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer N/A
Not yet recruiting NCT05988372 - Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE) Phase 2
Completed NCT00744640 - Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma Phase 1/Phase 2
Completed NCT03126435 - EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX Phase 3
Enrolling by invitation NCT01063192 - A Study of Locally Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT06429904 - Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer Phase 2
Recruiting NCT03885219 - Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT03468335 - 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy Phase 3
Not yet recruiting NCT03443921 - Divestment for Artery-involved Pancreatic Cancer N/A
Recruiting NCT03257033 - Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC Phase 3
Completed NCT02578732 - FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial Phase 2
Recruiting NCT04789980 - Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX therapY
Completed NCT00644618 - Randomized Controlled Trial of Gemcitabine Combined With 125I Brachytherapy Phase 3
Recruiting NCT03682289 - Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors Phase 2
Terminated NCT02404363 - Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy Phase 3
Active, not recruiting NCT06353581 - Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX Phase 2
Not yet recruiting NCT03815461 - Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer Phase 2
Recruiting NCT02898649 - Safety and Efficacy of Irreversible Electroporation for Locally Advanced Pancreatic Cancer N/A